血液或骨髓移植后皮肤恶性肿瘤的发病率与危险因素
这项回顾性队列研究纳入3880例血液或骨髓移植(BMT)后存活≥2年的患者及同胞对照,随访中位9.5年,发现30年任何皮肤恶性肿瘤累积发病率为27.4%。年龄≥50岁、男性、移植前单克隆抗体暴露、异基因BMT合并慢性移植物抗宿主病(cGVHD)、移植后免疫抑制及移植中心与风险升高相关,非西班牙裔白人以外种族风险较低。
要点
- BMT幸存者30年皮肤恶性肿瘤累积发病率为27.4%,以基底细胞癌(BCC)最常见。
- 异基因BMT合并cGVHD、移植后免疫抑制及年龄≥50岁是皮肤癌主要危险因素。
- 非西班牙裔白人以外种族对BCC和SCC风险较低,提示需个体化皮肤科监测。
核心结论
- BMT幸存者皮肤恶性肿瘤风险高,且存在恶性特异性危险因素,需个体化患者咨询和移植后皮肤科监测。
研究设计与样本
- 回顾性队列研究(BMT Survivor Study),纳入1974至2014年在三个中心接受BMT且存活≥2年的3880例患者,并设同胞对照队列。
主要发现
- 中位随访9.5年,605例发生778处皮肤恶性肿瘤(BCC 321例,SCC 231例,黑色素瘤78例,类型不明148例)。
- 任何皮肤恶性肿瘤30年累积发病率为27.4%(BCC 18.0%,SCC 9.8%,黑色素瘤3.7%)。
关键数值与推荐
- 年龄≥50岁(vs <50岁)与BCC风险相关(SHR 1.76,95%CI 1.36-2.29)及SCC风险相关(SHR 3.37,95%CI 2.41-4.72)。
- 男性与BCC风险相关(SHR 1.39,95%CI 1.10-1.75)及SCC风险相关(SHR 1.85,95%CI 1.39-2.45)。
- 移植前单克隆抗体暴露与BCC风险相关(SHR 1.71,95%CI 1.27-2.31)。
- 异基因BMT合并cGVHD(参照自体外周血干细胞移植)与BCC风险相关(SHR 1.48,95%CI 1.06-2.08)及SCC风险相关(SHR 2.61,95%CI 1.68-4.04)。
- 移植后免疫抑制与BCC(SHR 1.63,95%CI 1.24-2.14)、SCC(SHR 1.48,95%CI 1.09-2.02)及黑色素瘤(SHR 1.90,95%CI 1.16-3.12)风险相关。
临床怎么用
- 对BMT幸存者,尤其年龄≥50岁、男性、有cGVHD、移植后免疫抑制或移植前单克隆抗体暴露者,应加强皮肤癌筛查与咨询。
- 针对BCC、SCC和黑色素瘤的不同风险特征,可考虑个体化皮肤科随访策略。
局限性
- 回顾性队列设计,可能存在回忆偏倚和未测量混杂。
- 仅纳入三个移植中心且存活≥2年的患者,外推性受限。
- 皮肤肿瘤类型不明者148例,可能影响分类准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cutaneous malignant neoplasms are the most common subsequent neoplasm after blood or marrow transplant (BMT), but a full assessment among survivors is lacking. OBJECTIVE: To identify risk factors for subsequent cutaneous malignant neoplasms using the BMT Survivor Study (BMTSS). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients who underwent transplant from 1974 to 2014 at City of Hope, University of Minnesota, or University of Alabama at Birmingham and survived 2 years or longer, as well as a comparison cohort of siblings. Both groups completed the BMTSS survey. Data analysis took place from October 2022 to October 2024. EXPOSURES: Demographics, pre-BMT and BMT-related therapeutic exposures, chronic graft-vs-host disease (cGVHD), and posttransplant immunosuppression. MAIN OUTCOMES AND MEASURES: Incident cutaneous malignant neoplasms (basal cell carcinoma [BCC], squamous cell carcinoma [SCC], and melanoma) after BMT. Exposures were evaluated for association with subsequent neoplasms using proportional subdistribution hazards models (reported as subdistribution hazard ratio [SHR] and 95% CI). RESULTS: Among the 3880 BMT survivors (median [range] age at BMT, 44.0 [0-78.0] years; 2165 [55.8%] male; 190 [4.9%] Black, 468 [12.1%] Hispanic, 2897 [74.7%] non-Hispanic White, and 325 [8.4%] of other race [including Asian and Pacific Islander] and multiracial) who were followed up for a median (range) of 9.5 (2.0-46.0) years, 605 developed 778 distinct cutaneous neoplasms (BCC, 321; SCC, 231; melanoma, 78; and unknown type, 148). The 30-year cumulative incidence of any cutaneous malignant neoplasm was 27.4% (BCC, 18.0%; SCC, 9.8%; and melanoma, 3.7%). Seventy-year cumulative probabilities of BCC, SCC, and melanoma were considerably higher in BMT survivors than siblings (18.1% vs 8.2%, 14.7% vs 4.2%, and 4.2% vs 2.4%, respectively). Among BMT survivors, risk factors for subsequent cutaneous malignant neoplasms included age of 50 years and older at BMT (BCC: SHR, 1.76; 95% CI, 1.36-2.29; SCC: SHR, 3.37; 95% CI, 2.41-4.72), male sex (BCC: SHR, 1.39; 95% CI, 1.10-1.75; SCC: SHR, 1.85; 95% CI, 1.39-2.45), pre-BMT monoclonal antibody exposure (BCC: SHR, 1.71; 95% CI, 1.27-2.31), allogeneic BMT with cGVHD (BCC: SHR, 1.48; 95% CI, 1.06-2.08; SCC: SHR, 2.61; 95% CI, 1.68-4.04 [reference: autologous BMT]), post-BMT immunosuppression (BCC: SHR, 1.63; 95% CI, 1.24-2.14; SCC: SHR, 1.48; 95% CI, 1.09-2.02; melanoma: SHR, 1.90; 95% CI, 1.16-3.12), and transplant at City of Hope (BCC: SHR, 3.55; 95% CI, 2.58-4.89; SCC: SHR, 3.57; 95% CI, 2.34-5.47 [reference: University of Minnesota]) or University of Alabama at Birmingham (BCC: SHR, 2.35; 95% CI, 1.35-4.23; SCC: SHR, 2.63; 95% CI, 1.36-5.08 [reference: University of Minnesota]). Race and ethnicity other than non-Hispanic White were protective for BCC (Black: no cases; Hispanic: SHR, 0.27; 95% CI, 0.16-0.44; other race and multiracial: SHR, 0.26; 95% CI, 0.14-0.50 [reference: non-Hispanic White]) and SCC (Black: SHR, 0.17; 95% CI, 0.04-0.67; Hispanic: SHR, 0.28; 95% CI, 0.16-0.50; other race and multiracial: SHR, 0.13; 95% CI, 0.05-0.37 [reference: non-Hispanic White]). Total body irradiation was associated with BCC risk among those younger than 50 years at BMT (SHR, 1.92; 95% CI, 1.27-2.92). CONCLUSIONS AND RELEVANCE: In this cohort study, the high risk of cutaneous malignant neoplasms and malignant-specific risk factors suggest a need for personalized patient counseling and posttransplant dermatologic surveillance.
引用
- Broman KK, Meng Q, Holmqvist A, et al. Incidence of and Risk Factors for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant. JAMA Dermatol. 2025. PMID: 39693095. doi:10.1001/jamadermatol.2024.5129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。